T he onset and progression of allergic asthma is accompanied by a complex series of overlapping and often concurrent inflammatory responses in the lung orchestrated by CD4
ϩ Th2 lymphocytes (1) (2) (3) (4) (5) . These responses include T cellmediated help of Ag-specific Ig production, particularly IgG1 and IgE, by B cells (6, 7) , expression of Th2 proinflammatory cytokines (e.g., IL-4, IL-5, and IL-13 ( 8 -10) ), and the activation of vascular endothelial cells leading to the release of chemokines (11) as well as increases in adhesion molecule receptors (12, 13) . Asthma-associated pulmonary inflammation is characterized by cellular infiltrates, and subsequently, histopathologies that are thought to be the underlying cause(s) of the accompanying airway obstruction and lung dysfunction. In particular, the differential recruitment of eosinophils to the airway mucosa and lumen are common features of allergic respiratory disease, occurring in Ͼ75% of reported cases (14) . This selective recruitment suggested that pulmonary pathologies arise, in part, as a consequence of eosinophil effector functions. Indeed, studies have implicated eosinophils as immunoregulative cells modulating the inflammatory response (15, 16) as well as proinflammatory cells whose activities lead to epithelial desquamation, airway smooth muscle perturbation, and tissue remodeling (17) .
The prominent effector functions mediated by eosinophils appear to result from the release of abundant cationic proteins from morphologically distinct cytoplasmic granules through a process known as degranulation (18) . The most abundant of these granule proteins (by mass) is a cationic heme-containing protein identified as eosinophil peroxidase (EPO).
3 EPO appears to be specific for the eosinophil cell type and represents nearly 25% of the total protein mass of the secondary granule (19) . The release of EPO, together with the generation of the reduced oxygen species (i.e., superoxide and hydrogen peroxide) resulting from the respiratory burst of activated eosinophils (20) , provides a potent defense mechanism (e.g., peroxidase-mediated generation of hypohalous acids (21) ) capable of killing invading pathogens such as bacteria (22) and multicellular helminth parasites (23, 24) . Moreover, EPO activities have been shown to be potentially immunoregulative, triggering mast cell degranulation (25) , activating platelets (26) , and increasing the respiratory burst/phagocytic capabilities of macrophages (27) . A series of provocative studies examining the biochemistry of EPO activity also suggested that the release of this granule protein during allergic inflammatory responses results in oxidative damage of resident lung proteins by nitration or bromination of tyrosine residues (28, 29) . The generation of 3-bromotyrosine is particularly important because this was shown to be an EPO-specific product that increases Ͼ10-fold in bronchoalveolar lavage (BAL) fluid recovered from asthmatic, but not healthy control, subjects after segmental allergen challenge (30) . Moreover, nearly 100-fold increases in 3-bromotyrosine content were observed in BAL fluid recovered from subjects with severe asthma who had been admitted to an intensive care unit compared with nonasthmatic patients (31) .
Cases of EPO deficiency (Presentey's anomaly) have been documented in a number of patients and are characterized by the absence or attenuation of cytochemical staining for eosinophil-derived peroxidase and a significant loss in the volume of the eosinophil secondary granule occupied by the electron-translucent matrix (32) . However, notable clinical symptoms were absent in these cases, as the identification of EPO-deficient patients occurred randomly during studies unrelated to asthma or allergic disease (33) . A similar EPO deficiency was also described in a unique substrain of New Zealand White (NZW) mice (34) . This deficiency in NZW mice led to comparable effects (i.e., relative to human EPO-deficient patients) on the electron microscopic ultrastructure of eosinophil secondary granules. Unfortunately, the random genetic aberration occurring in NZW mice is not well characterized and may include perturbations of other loci in addition to EPO.
We have created a null allele at the EPO locus in the mouse to define specific effector functions mediated by this eosinophil granule protein during allergic pulmonary disease. Eosinophils from homozygous null EPO mice (EPO Ϫ/Ϫ ) were shown to be deficient of peroxidase activity and displayed the same decrease in the electron-translucent matrix of the secondary granules observed in both NZW mice and EPO-deficient patients. OVA sensitization/aerosol challenge of wild-type and EPO Ϫ/Ϫ mice demonstrated that the EPO deficiency had no effects on the development of airway pathologies including OVA-induced airway hyperresponsiveness (AHR) following methacholine provocation. Furthermore, the extent of EPO-dependent modification of BAL proteins from OVAchallenged mice was Ͻ10% of the values reported from humans following either allergen challenge or asthma-related respiratory failure. The lack of visual evidence of eosinophil degranulation in mouse OVA models, together with no observable differences (i.e., relative to wild-type littermates) in the OVA-mediated pathologies occurring in EPO Ϫ/Ϫ mice or mice deficient for major basic protein (MBP)-1 (35) , suggest that the release of eosinophil secondary granule proteins (ESGPs) is not a prominent effector function in mouse models of respiratory inflammation.
Materials and Methods

Targeted deletion of the EPO locus and generation of knockout mice
An EPO gene-targeting vector was constructed using 129/SvJ-derived genomic DNA flanking a 3.9-kb fragment containing exons 6, 7, and 8 of this gene (36) . The targeting vector replaces these exons with a neomycin resistance cassette (PGK-neo) and also includes the diphtheria toxin A gene as a negative selection marker (Fig. 1A) . The targeting construct (25 g) was linearized and introduced into 4 ϫ 10 7 GK-129 embryonic stem (ES) cells (37) via electroporation. Transfectants were selected on the basis of growth in the presence of 400 g/ml G418. Surviving GK-129 ES cell clones were analyzed by Southern blot of SpeI-digested DNA to identify heterozygous disruptions of the EPO gene using a probe flanking the 5Ј homology region of the targeting vector (probe 1). A single integration event was verified by Southern blot of BamHI/BclI-digested DNA using a probe derived from the neomycin resistance gene (probe 2; data not shown). Targeted GK-129 ES cells from clones 6 and 57 were injected into C57BL/6J blastocysts to generate chimeric animals that were bred to 129/ SvJ mice, allowing the transmission of this allele on a 129-inbred background (129/Ola/Hsd ϫ 129/SvJ). Mice were maintained in microisolator cages housed in a specific pathogen-free facility. The sentinel cages within this animal colony surveyed negative for viral Abs and the presence of known mouse pathogens. Protocols and studies involving animals were conducted in accordance with National Institutes of Health and Mayo Foundation institutional guidelines.
DNA recovered from tail biopsies was used as a template in PCRs to genotype potential animals carrying the EPO targeted allele. Animals were identified as wild type ϩ/ϩ, heterozygous (EPO ϩ/Ϫ ), or homozygous (EPO Ϫ/Ϫ ) mice using a three-primer strategy. The location and orientation of the primers are shown in Fig. 1A . The wild-type allele was identified as a 750-bp PCR amplicon using sequence information derived from exon 8 (primer 1 (P 1 ), 5Ј-TGAAACCCCCAAACTGACGG-3Ј) and exon 9 (primer 2 (P 2 ), 5Ј-ACAGAGCTAAGCGGGACGTG-3Ј). The targeted EPO locus was identified as a 1000-bp PCR amplicon using P 2 and a primer derived from the neomycin-resistance gene (primer 3 (P 3 ), 5Ј-CATCGA GCGAGCACGTACTC-3Ј). PCRs were assembled in 100-l volumes using the GeneAmp XL-PCR kit (PerkinElmer Applied Biosystems, Foster City, CA) and a cycling strategy of 94°C for 5 min followed by 30 cycles of 94°C (1 min), 57°C (2.5 min), 72°C (2 min), and a final extension of 72°C for 7 min.
RNA isolation and RT-PCR analysis
Total RNA was prepared from bone marrow, liver, lung, and spleen of ϩ/ϩ, EPO ϩ/Ϫ , or EPO Ϫ/Ϫ animals by homogenization in a guanidinium isothiocyanate buffer followed by acid phenol extraction and ethanol precipitation (38) . RNA samples were treated with RNase-free DNase I (RQ1; Promega, Madison, WI) for 30 min at 37°C, followed by phenol/chloroform extraction and ethanol precipitation before reverse transcription reactions. Total RNA (1 g) was reverse transcribed with SuperScript II reverse transcriptase (Life Technologies, Rockville, MD) in the presence of anchored oligo(dT) primers (dT 16 VN where V ϭ A, C, or G and N ϭ A, C, G, or T) according to the manufacturer's instructions. PCRs were performed using cDNA derived from one-tenth of the reverse transcriptase reactions (i.e., cDNA derived from 100 ng total RNA) in 50-l reactions with 1 M of EPO-specific primers and 5 U Taq polymerase (Boehringer Mannheim, Indianapolis, IN). EPO transcripts were identified in the samples as a 263-bp amplicon. The location and orientation of the RT-PCR primers (P 1 and P 4 , 5Ј-TGAAAACATTGGCTACACGG-3Ј) are shown in Fig. 1A . A ␤-actin primer set (Stratagene, La Jolla, CA) was used as a positive control for the RT-PCR. All PCRs were performed in duplicate using 100 ng total RNA in the absence of reverse transcription as a negative control (data not shown). The PCRs were conducted using a thermocycle profile of 94°C for 5 min followed by 30 cycles of 94°C (30 s), 58°C (2 min), 72°C (3 min), and a final extension of 72°C for 10 min.
Induction of peritoneal cavity eosinophilia
Large numbers of eosinophils (Ͼ2 ϫ 10 6 , 20 -30% eosinophils) were induced in the peritoneal cavity of mice via a sensitization/challenge protocol using a whole-protein extract from the helminth Mesocestoides corti, MCA) (39) . Briefly, ϩ/ϩ, EPO ϩ/Ϫ , or EPO Ϫ/Ϫ animals were initially sensitized with a 400-l s.c. injection of 8 ϫ 10 9 killed pertussis organisms (Michigan Department of Public Health, Lansing, MI) and 250 g MCA suspended in sterile saline. Twenty-one days later mice were challenged with a 300-l i.p. injection of 200 g MCA in sterile saline. Peritoneal cavity cells were harvested 3 days later by lavage with 1ϫ PBS, 5% FCS, and 20 U/ml heparin. Recovered leukocytes were washed several times by centrifugation/resuspension in 1ϫ PBS before use in subsequent experiments. Differential counts of cytospin preparations of these cells reveal that neutrophils composed Ͻ1% of all samples examined.
Cytochemical detection of EPO
Cytospin preparations of peritoneal cavity cells harvested from MCA-sensitized/challenged mice were prepared using a Cytospin3 (Shandon Scientific, Cheshire, U.K.). The slides were subsequently fixed for 30 s at 4°C in a formalin-acetone buffer (0.75 mM Na 2 HPO 4 , 7.5 mM KH 2 PO4 (pH 7.5), 45% (v/v) acetone, and 10% (w/v) formaldehyde), washed in tap water for several minutes, and stained (10 min at room temperature) for EPO activity using a diaminobenzidine (DAB)-H 2 O 2 phosphate buffer (6 mM Na 2 HPO 4 , 286 mM KH 2 PO 4 (pH 7.4), 2 mM (3Ј,3Ј)-DAB tetrahydrochloride (Sigma, St. Louis, MO), 0.01% H 2 O 2 (Sigma), and 8 mM NaCN (Aldrich, Milwaukee, WI)) as described earlier (36) . The concentration of CN Ϫ included in this reaction buffer was selected to differentially inhibit the activity of myeloperoxidase found in other leukocyte types that may be present. The staining reactions were terminated by washing under tap water, and the slides were counterstained with Harris hematoxylin (Sigma) before dehydration through an ascending series of ethanol washes, incubation in xylene, and mounting with Permount (Fisher Scientific, Pittsburgh, PA).
Endpoint colorimetric assessment of EPO activity
The amount of EPO activity contained within cells or recovered fluids was determined by an endpoint colorimetric assay, as described previously (40) . To determine the amount of EPO activity within cells, peritoneal cavity cells and/or leukocytes recovered from BAL fluid were washed in Kreb's buffer (118 mM NaCl, 25 mM NaHCO 3 , 11 mM glucose, 1 mM NaH 2 PO 4 ⅐H 2 O, 5 mM KCl, 0.5 mM MgCl 2 ⅐6H 2 O, and 2.5 mM CaCl 2 ⅐6H 2 O (pH 7.4)) and counted on a hemocytometer. The number of eosinophils in a given leukocyte population was determined by differential cell counts of cytospin preparations. (41) . Colorimetric readings due to EPO activity were calculated as the difference in absorbance measurement of each reaction with a duplicate reaction conducted in the presence (30 mM) of the peroxidase inhibitor 3-amino-1,2,4-triazole. The fraction of EPO released from airway eosinophils was estimated by measuring the amount of EPO activity in cell-free BAL fluid as a function of total EPO activity in the BAL (i.e., the sum of EPO in the BAL fluid and EPO associated with airway eosinophils). EPO activity was calculated from a standard curve established using 1 ϫ 10 2 -5 ϫ 10 5 eosinophils purified as a homogeneous population (99% pure) from an IL-5-transgenic mouse line (42) . The A 490 reading of each sample (i.e., the BAL fluid and BAL cell pellet derived from each mouse) was used to obtain the equivalent amount of EPO contained in a known number of eosinophils as determined from this standing curve.
Electron microscopy of leukocytes
Peritoneal cavity exudates of mice sensitized/challenged with M. corti protein extract were collected by lavage and concentrated by low speed centrifugation (1000 rpm, 4°C). The leukocytes of this low speed pellet were resuspended directly in Trump's fixative (4% formaldehyde, 0.5% gluteraldehyde, and 84 mM NaH 2 PO 4 (pH 7.2)) and stored at room temperature before application on electron microscopy grids.
Induction of allergic airway inflammation
Wild-type and EPO Ϫ/Ϫ mice littermates, age 8 -12 wk, were sensitized by two i.p. injections of either saline or 20 g OVA (grade IV, Sigma)-2.25 mg Imject Alum (Al(OH) 3 -Mg(OH) 2 ; Pierce, Rockford, IL) in 100 l saline on days 0 and 14. Mice were challenged on days 24, 25, and 26 by 20-min inhalations of an aerosol generated by nebulization of a 1% OVA solution prepared in saline (control mice received 20-min aerosol challenges of saline). Mice were assessed for pulmonary cellular infiltrates, histopathologies, and lung function on day 28.
Assessments of allergic airway inflammation: pulmonary cellular infiltrates and Ag-induced histopathologies
The number and specificity of cell types recruited to the airspaces were determined by BAL as previously described (43) . Histopathologic changes to the airways and parenchyma, including mucus cell content of the epithelium, were assessed from lungs excised and fixed in 10% buffered formalin overnight at 4°C (lungs were inflated with a fixed volume (0.5 ml) of fixative). The lung samples were washed free of formalin with 1ϫ PBS and dehydrated through an ascending ethanol series before equilibration in xylene and embedding in paraffin. Parasagittal sections (4 m) were stained with periodic acid-Schiff reagent (PAS) and counterstained with hematoxylin-methyl green to assess mucus production and goblet cell metaplasia. Three sections per lung were examined, and the mucus content of ϳ40 airways (proximal and distal) per section were measured from groups of six animals. An imaging program (Image ProPlus; Media Cybernetics, Silver Spring, MD) was used to quantify the area and intensity of PAS staining per airway. The data were quantified as a mucus index: [(average PAS staining intensity of the airway epithelium) ϫ (area of airway epithelium staining with PAS)/(total area of the conducting airway epithelium) ϫ (total number of airways assessed)].
Immunocytochemical detection of eosinophils
Sections of lung tissue (4 m) were assessed for the infiltration of eosinophils using a rat mAb (14.7.4) specific for murine MBP-1 (35) . Immunocytochemical staining was performed with DAB-peroxidase detection reagents (Vector Laboratories, Burlingame, CA) as described previously (35) .
Determination of bromotyrosine levels in the lung
The 3-bromotyrosine content of proteins recovered from the BAL and whole-lung homogenates of mice was determined (relative to the precursor amino acid, i.e., tyrosine) by stable isotope-dilution gas chromatography/ mass spectrometry (44) . Sample preparation and specific methodologies used were as described earlier (29, 30) . The 3-bromotyrosine levels in human subjects were derived from data of earlier clinical studies assessing oxidative damage of pulmonary proteins occurring in asthma patients (30, 31) .
Assessment of AHR in response to methacholine challenge
AHR was assessed by inducing airflow obstruction with a methacholine aerosol using a noninvasive protocol (43, 45) . This methodology uses unrestrained, conscious mice that are placed into the main chamber of a plethysmograph (Buxco Electronics, Troy, NY.). Pressure differences between this chamber and a reference chamber were used to extrapolate minute volume, tidal volume, breathing frequency, and enhanced pause (PENH). PENH is a dimensionless parameter that is a function of total pulmonary airflow in mice (i.e., the sum of the airflows in the upper and lower respiratory tracts) during the respiratory cycle of the animal. This parameter was shown to closely correlate with airway resistance as measured by traditional invasive techniques using ventilated animals (43) . Dose-response data were plotted as the percent baseline PENH vs the log 10 of the methacholine solution (mg/ml) used to generate the aerosol. There were no statistically significant differences (Tukey-Kramer honestly significant difference test) observed among the baseline PENH values (Ϯ SE) of the different animal groups used in these studies: wild-type (ϩ/ϩ) saline, 0.51 Ϯ 0.03; wild-type (ϩ/ϩ) OVA, 0.49 Ϯ 0.03; EPO Ϫ/Ϫ saline, 0.52 Ϯ 0.04; and EPO Ϫ/Ϫ OVA, 0.55 Ϯ 0.05.
Statistical analyses
Unless otherwise indicated, pairs of groups were compared using Student's t tests. The p value for significance was set at 0.05, and values for all measurements are expressed as the mean Ϯ SEM.
Results
The generation of EPO-deficient mice
Mouse eosinophils have been shown to express, and subsequently store in secondary granules, a peroxidase that is uniquely associated with this cell type (36) . This ESGP is encoded by a single gene that represents the mouse orthologue of human EPO (36, 46) . A targeting construct was generated from 129/SvJ -genomic clones representing the EPO locus and designed to replace exons 6, 7, and 8 of this gene with a neomycin-resistance cassette (Fig.  1A) . These exons contain the conserved histidine and arginine residues essential to catalytic activity and are present in all members of this gene superfamily (36, 47, 48) . Moreover, these exons also contain six half-cystine residues involved in disulfide linkages and 11 residues whose location within 4.5 Å of the heme prosthetic group suggest that they are essential to stabilize this motif (49) . This targeting construct was transfected into GK-129 ES cells, and heterozygous disruptions of the EPO gene were identified by Southern blot as shown in Fig. 1B . Targeted ES cell clones were injected into C57BL/6J blastocysts, and the resulting chimeric males were bred to 129/SvJ females to transmit this mutant allele through the germline. Homozygous EPO-knockout mice were generated by sibling intercross (Fig. 1C) and, thus, remained on a pure 129 genetic background. The targeted EPO gene was transmitted to offspring at the expected Mendelian frequency, and matings of EPO Ϫ/Ϫ mice produced litters of a size and frequency equivalent to wild-type or heterozygous animals. All studies described in this report were performed with EPO Ϫ/Ϫ and wild-type siblings derived from matings of EPO ϩ/Ϫ mice. RT-PCR was used to assess gene expression in EPO Ϫ/Ϫ mice and to confirm that these animals did not express EPO transcripts. Fig. 1D shows that expression of EPO was restricted to wild-type and EPO ϩ/Ϫ mice and occurred only in bone marrow and spleen, tissues previously shown to be sites of eosinophilopoiesis and EPO gene expression (36) .
The loss of EPO results in ultrastructural changes of the eosinophil secondary granule
In contrast to the loss of MBP-1 (35) , which results in the elimination of the electron dense core of the secondary granule, EPO Ϫ/Ϫ peritoneal cavity exudate cells recovered following sensitization/challenge of mice with a whole-protein extract from the helminth M. Corti-contained granules with both the electron dense core structure and electron translucent matrix surrounding this core (Fig. 2) . Moreover, the average number of granules per cross-sectional area was found to be the same in wild-type and EPO
of the matrix) reduces the fraction of the granule occupied by the matrix such that granules recovered from EPO Ϫ/Ϫ eosinophils are ϳ57% the size of wild-type granules, indicating that the matrix volume results, in part, by the physical presence of EPO.
Eosinophils from knockout mice are peroxidase deficient
The loss of EPO activity in knockout mice was demonstrated by cytochemical staining of peritoneal cavity exudate cells recovered following sensitization/challenge of mice with a whole-protein extract from the helminth M. corti. Fig. 3A shows that eosinophils from EPO Ϫ/Ϫ mice were devoid of peroxidase activity (i.e., CN Ϫ -resistant peroxidase activity (DAB staining) was present only in eosinophils from wild-type and EPO ϩ/Ϫ mice). The loss of peroxidase activity in cells from EPO Ϫ/Ϫ mice was further demonstrated using an endpoint colorimetric assay detecting EPO in lysates of the peritoneal cavity exudates (Fig. 3B) . The peroxidase activity of EPO ϩ/Ϫ eosinophils was roughly 50% of that found in wild-type eosinophils, suggesting that EPO levels in eosinophils are proportional to the number of wild-type EPO loci present. Eosinophils recovered from homozygous knockout mice derived from ES cell clone 6 or 57 were shown to be EPO deficient using both the peroxidase cytochemical detection methodology and the endpoint colorimetric assay. Thus, mice derived from either ES clone were considered equivalent, and subsequent studies were performed on animals derived from clone 57.
The loss of peroxidase activity in knockout animals was functionally demonstrated by assessing an EPO-specific oxidation product, bromotyrosine, in whole-lung homogenates from wildtype and EPO Ϫ/Ϫ mice using an OVA i.p. sensitization/aerosol challenge model of respiratory inflammation. The localization of eosinophils within compartments of the lung after OVA (or saline) challenge was initially assessed with an anti-mouse MBP rat mAb that was previously demonstrated to be specific for eosinophils (35) . Fig. 4 shows that although small numbers of eosinophils are homeostatic resident cells in the lungs of both wild-type and EPO Ϫ/Ϫ mice, OVA challenge resulted in an influx of eosinophils into the peribronchial/perivascular regions of both genotypes. The localization and number of eosinophils (150 -200 eosinophils per millimeter squared) in the lungs after OVA challenge were indistinguishable between wild-type and EPO Ϫ/Ϫ mice. As suggested by earlier studies demonstrating the colocalization of EPO activity and peroxidase-mediated oxidation products in eosinophils recruited to the lung (31, 50), 3-bromotyrosine levels (as a fraction of unmodified tyrosine residues present) increased in whole-lung homogenates of OVA-treated wild-type mice relative to salinechallenged controls (Fig. 5) . In contrast, the 3-bromotyrosine/tyrosine levels in whole-lung homogenates were undetectable in saline-treated control or OVA-treated EPO Ϫ/Ϫ mice, the latter despite an Ag-induced pulmonary eosinophilia equivalent to wildtype mice (Fig. 5) . The area of the electron translucent matrix and, therefore, the size of the secondary granule itself is dependent on the presence of EPO. Eosinophils from peritoneal cavity exudates of parasite Ag-sensitized/challenged mice were fixed and subjected to electron microscopy. Electron photomicrographs showing clusters of secondary granules from wild type (ϩ/ϩ) and EPO Ϫ/Ϫ mice are presented in comparison with a photomicrograph of secondary granules derived from eosinophils of a MBP-1 Ϫ/Ϫ animal. It is noteworthy that the presence or absence of EPO substantively affects the area of the granule occupied by the electron translucent matrix (and as a result the absolute size of the granule), whereas loss of MBP-1 obviates only the electron dense core with little effect on granule size (35) . The original magnification of all the photomicrographs presented is ϫ27,500.
FIGURE 3. EPO activity is absent in the eosinophils of knockout mice. A, EPO activity is detected only in wild-type and EPO
ϩ/Ϫ eosinophils recruited in response to Ag challenge. Peritoneal cavity exudates of parasite Ag-sensitized/challenged wild-type, EPO ϩ/Ϫ , and EPO Ϫ/Ϫ mice (39) were subjected to cytochemical staining for peroxidase activity with a H 2 O 2 -DAB substrate solution (sodium cyanide was included in the staining reactions to limit detection only to EPO-derived peroxidase activity). Identifications of specific leukocyte types were based on nuclear/cytoplasmic morphology. B, EPO activity is present in eosinophils in direct proportion to the number of wild-type alleles. An endpoint colorimetric assay was used to assess peroxidase activity in lysates derived from exudates following parasite Ag sensitization/challenge. Assessments of peroxidase activity (absorbance at 490 nm), plotted as a function of the number of eosinophils in the peritoneal cavity exudate, demonstrate that EPO ϩ/Ϫ eosinophils contain half the peroxidase activity as wild-type (ϩ/ϩ) cells. In comparison, measurable peroxidase activity was undetectable in exudate cell lysates from EPO Ϫ/Ϫ mice regardless of the input number of eosinophils. The points comprising each curve represent the means of assays performed on exudate cells derived from four different animals within each group. Error bars at each point represent Ϯ SEM.
OVA-induced pulmonary inflammation leads to airway recruitment of eosinophils in both wild-type and EPO Ϫ/Ϫ mice
In response to OVA provocation, equivalent numbers of eosinophils were recruited to the BAL fluid of wild-type and EPO Ϫ/Ϫ mice in a time-dependent fashion following the last OVA aerosol challenge (data not shown). Maximal recruitment of eosinophils occurred in both genotypes 48 h after the final aerosol challenge (Table I) . Moreover, a detailed differential assessment of cells recruited to the BAL 48 h after challenge revealed that the loss of EPO had no effects on the recruitment of any leukocyte types relative to OVA-treated wild-type controls (Fig. 6) ; aerosol challenge with saline alone had no effect on the homeostatic levels of cells in the airspaces of mice of either genotype.
The targeted deletion of EPO in knockout mice did not affect the lung histopathologies occurring in response to OVA challenge
Wild-type and EPO Ϫ/Ϫ mice displayed identical airway changes in response to OVA sensitization/challenge. For example, PAS staining of lung sections demonstrated that the airway epithelia of both wild-type and EPO Ϫ/Ϫ mice exhibit increased mucus content in response to OVA challenge (Fig. 7) . Moreover, this increase was indistinguishable between genotypes and occurred in the bronchi as well as the more distal airways (i.e., bronchioles).
The AHR associated with OVA sensitization/challenge models occurs in EPO-deficient mice
The potential role(s) of EPO in the development of Ag-induced AHR to methacholine provocation was assessed by whole-body plethysmography of wild-type and EPO Ϫ/Ϫ mice. The resulting dose response curves (means of single-animal measurements; n ϭ 12-16 mice per group) are presented in Fig. 8 . These data compare the responses of wild-type and EPO Ϫ/Ϫ mice that have been challenged with saline or OVA. The dose responses of both salinechallenged groups were identical, indicating no significant role of EPO at baseline. Furthermore, OVA-sensitized/challenged wildtype and EPO Ϫ/Ϫ mice each displayed identical increases in methacholine-induced airflow changes relative to the saline-challenged control groups (i.e., AHR), indicating responses to allergen-challenge in both genotypes. In addition, no significant differences were observed in the dose-response curves of OVAsensitized/aerosol-challenged wild-type and EPO Ϫ/Ϫ mice. Thus, the Ag-induced AHR in this OVA model of asthma occurs independently of EPO.
The allergen-induced recruitment of eosinophils to the airways is not accompanied by a concomitant release of EPO
Assessments of EPO in cell-free BAL relative to EPO activity associated with eosinophils recruited to the airways demonstrated that the recruitment of airway eosinophils is not accompanied by a significant release of EPO activity into the BAL (Table I) . EPO activity in the BAL increased as a function of airway eosinophil number (i.e., time after challenge; data not shown). At the point of maximal eosinophil airway recruitment (i.e., 48 h after challenge), only nominal amounts of EPO were found in the cell-free BAL relative to the activity contained within recruited airway eosinophils (i.e., ϳ9% of total activity). No measurable EPO was detected in BAL fluid from EPO Ϫ/Ϫ mice. Furthermore, this limited release of EPO by eosinophils recruited to the airway lumen of OVA-treated mice is reflected by nominal 3-bromotyrosine/tyrosine levels in proteins from the BAL (Fig. 9) . This result is a significant departure from observations of asthma patients because the BAL fluid of both severe asthmatics in an intensive care unit, as well as mild asthmatics 48 h after segmental Ag challenge, each mice. No differences in the number or specific location of eosinophils recruited to the lung were observed between similarly treated mice of either genotype. Scale bar ϭ 100 m.
FIGURE 5.
Bromotyrosine levels in the lungs of wild-type mice increase concomitantly with the recruitment of eosinophils and are uniquely mediated by EPO. The lungs of wild-type (ϩ/ϩ) and EPO Ϫ/Ϫ mice were harvested 48 h following the last OVA aerosol challenge (i.e., the maxima of postchallenge eosinophilia), and the 3-bromotyrosine/tyrosine content of whole-lung homogenates was determined as described in Materials and Methods. Significant levels of 3-bromotyrosine accompany the pulmonary eosinophilia of wild-type mice, whereas EPO Ϫ/Ϫ animals do not elaborate 3-bromotyrosine levels following OVA sensitization/challenge. Data represent the mean Ϯ SD.
displayed Ͼ10-fold higher 3-bromotyrosine/tyrosine levels relative to the mouse and/or healthy control subjects (Fig. 9) .
Discussion
The paradigm and, in many respects, the dogma associated with the execution of eosinophil effector functions in the lungs during allergic inflammation centers on the release of cationic ESGPs by a process generally known as degranulation (51) (52) (53) . Although some debate exists in the literature as to the exact nature of this release in the airways of asthmatics (18), evidence exists demonstrating the existence of two likely mechanisms. Studies of asthma (see, for example, Ref. 54 ) and allergic rhinitis patients (55) provide visual evidence of an apparently controlled release of ESGPs known as "piecemeal degranulation" (i.e., the partial and/or complete release of granule proteins from otherwise intact eosinophils) (56) . Evidence for this mechanism of release has also been described in animal models of allergic pulmonary disease (e.g., guinea pig models of asthma; see Ref. 57 ) as well as other eosinophil-associated disease states in humans (58) . Moreover, Torpier and colleagues suggest that piecemeal degranulation represents a mechanism by which ESGPs are selectively released as part of a strategy to target these proteins within specific tissues (59) . In contrast, widespread evidence exists for a more dramatic, seemingly unregulated release of ESGPs via a mechanism defined as eosinophil cytolysis (i.e., catastrophic, nonapoptotic death resulting in the loss of plasma membrane integrity and the release of membrane-bound granules (clusters of free eosinophil granules Data from studies using the mouse as a model system of allergic pulmonary disease increasingly demonstrate that eosinophil degranulation may not occur in Ag-challenge protocols (62) . For example, eosinophils recruited to the lung remain intact, with no electron microscopic evidence of degranulation or cfegs in the airway lumen, and the literature abounds with studies demonstrating a lack of extracellular matrix-associated ESGP deposition in the lung using immunohistochemical/immunofluorescence staining with granule protein (MBP)-specific Ab reagents (Fig. 4 and Refs. 35, 63) . Furthermore, the paucity of studies in the literature (64) describing eosinophil-mediated tissue damage in the mouse (e.g., cilliostasis and epithelial sloughing) also suggests that although mouse eosinophils contain ESGPs that share considerable degrees of sequence identity with their human counterparts (36, 39, (65) (66) (67) , these proteins are apparently not released (and therefore do not execute effector functions) in OVA models of respiratory inflammation. This lack of degranulation in the mouse is supported by our observations of knockout mice deficient for genes encoding the abundant ESGPs, MBP-1, and now also EPO. The loss of MBP-1 in mice had no effect on the development of pulmonary pathologies in an OVA-challenge model. These observations extended beyond pulmonary histopathologies and airway changes, as MBP-1-deficient mice also displayed OVA-induced AHR after provocation with nonspecific stimuli (35) . The data reported here show that the OVA-induced pulmonary pathologies in EPO Ϫ/Ϫ mice are similarly not attenuated relative to wild-type littermates as a consequence of this ESGP deficiency.
Assessments of BAL fluids from OVA-treated wild-type mice indicate that only nominal amounts of free EPO activity are present (i.e., ϳ9% of the EPO present in the eosinophils recruited to the airspaces). In addition, only nominal levels of the EPOspecific oxidation product 3-bromotyrosine are observed in BALderived proteins. These data imply either that eosinophils recruited to the lung are each only releasing a small fraction of the available EPO (i.e., piecemeal degranulation) or that a subset of the recruited eosinophils are undergoing an overt release of EPO (i.e., cytolysis). Photo and electron microscopic evidence showing the integrity of eosinophils recruited to the lung (see, for example, Ref. 62) suggests that piecemeal degranulation and/or cytolysis by a subset of recruited eosinophils is unlikely, implying that low levels of EPO may be actively released by yet a third independent mechanism (e.g., de novo gene expression and secretion by activated eosinophils recruited to the airways). However, it is noteworthy that the free mouse EPO in the BAL may be artifactual, resulting as a consequence of hydrodynamic shear of a fraction of the eosinophils present during the recovery of BAL. Regardless of the resolution of this quandary, the presence of only nominal levels of 3-bromotyrosine in the proteins recovered from the BAL of OVAchallenged mice (i.e., Ͼ90% decrease relative to asthma patients) highlights a significant difference between humans and mice. Although this difference may simply reflect species differences in the turnover of oxidized proteins or the kinetics of EPO release, a more likely explanation is that release of EPO by mouse eosinophils recruited to the BAL is minimal, and/or concurrent events necessary to elicit EPO effector function (e.g., generation of reduced oxygen species by eosinophil respiratory burst) may be significantly reduced. The lack of phenotypic consequences associated with the loss of either EPO or MBP-1 suggest that neither of the two most abundant ESGPs in the mouse contribute to the pathologies observed in this model. However, these knockout mice do not rule out that other eosinophil-associated effector functions (e.g., Ag presentation (68, 69) or the release of cysteinyl leukotrienes (70, 71) ) lead to allergen-induced pathologies. Nonetheless, the implicit conclusion drawn from these studies is that mouse and human eosinophil effector functions are different, and the lack of degranulation in the mouse is a manifestation of this difference. This hypothesis is exemplified in the photographs of Fig. 10 which exemplify the absence of eosinophil degranulation in mouse models of Ag-mediated inflammation relative to the release of ESGPs in asthma patients. The images presented are compelling examples encapsulating the literature at large. The lung sections presented in Fig. 10 clearly show that human eosinophils recruited to the lungs of asthma patients display dramatic evidence of degranulation and extracellular matrix deposition of ESGPs such as human MBP. In contrast, peroxidase activity (i.e., the generation of nitrotyrosine) and MBP-1 each remain localized within recruited mouse eosinophils. The question that arises is, "What is the basis of this observed difference?" In particular, is the OVA model an inadequate representation of the inflammatory reactions occurring in asthma patients, or in other words, are there costimulatory signals missing in the mouse models preventing eosinophil degranulation? The inability of isolated mouse eosinophils either to undergo degranulation or generate significant amounts of 3-bromotyrosine after exposure to PMA (data not shown) suggests that the OVA models are not at issue. Instead, the difference in the mouse models and asthma patients apparently lies within the eosinophil itself. This would imply that selective evolutionary pressures on mouse vs human eosinophils during the 75-100 million years since the divergence of the mammalian orders Rodentia and Primata (72) have led to species differences in eosinophil-mediated activities. Specifically, it was (is) selectively advantageous for rodent and/or primate eosinophils to adopt different modes of executing effector functions that become apparent within the context of the artificial circumstances surrounding an OVA sensitization/challenge model system (i.e., eosinophil activities may contribute to pathology in mouse OVA models but not through an extensive release of ESGPs as occurs in asthma patients). However, a logical extension of this hypothesis is the convergence of eosinophil effector functions in mice and humans with regard to evolutionarily old defensive mechanisms (i.e., pathways predating the radiation of extant mammalian orders) such as eosinophil-mediated host defenses against parasites (73) . The observations of Pearlman and colleagues (74) demonstrating the deposition of extracellular MBP on the surface of airway epithelial cells in the lungs of mice responding to an active infestation of the parasite Onchocerca volvulus imply that, under specific circumstances, mouse eosinophils are capable of releasing ESGPs (i.e., degranulation) reminiscent of their human counterparts. Thus, although the necessity of degranulation to eosinophil effector function has remained critical, the mechanisms and/or circumstances required to elicit this event have evolved differently among mammalian orders. The absence of ESGP release in OVA mouse models, exemplified by attenuated levels of EPO-mediated protein oxidation relative to asthma patients, and the apparent lack of OVA-mediated pathologies in EPO and MBP-1 knockout mice is likely a reflection of this evolutionary difference in eosinophil effector function(s). FIGURE 9. 3-Bromotyrosine/tyrosine levels in cellfree BAL from allergen-sensitized/aerosol-challenged mice are decreased Ͼ90% relative to the observed levels occurring in asthma patients. BAL recovered from wild-type (C57BL/6J) mice 48 h following saline or OVA aerosol challenge were assessed for 3-bromotyrosine content and displayed as histograms relative to the 3-bromotyrosine content of BAL proteins recovered from healthy control subjects and a cohort of severe asthmatic patients ‫,ء(‬ data derived from studies described in Ref. 31 ) and mild asthmatic subjects following segmental allergen challenge ( †, data derived from studies described in Ref. 30 ). Numbers in parentheses represent the sample size of each group. Data represent the mean Ϯ SD.
FIGURE 10.
The eosinophil degranulation characteristic of asthma patients does not occur in OVA-sensitization/challenge mouse models. An example of the degranulation (i.e., deposition of MBP in the extracelluar matrix compartments of the lung) that potentially occurs in humans is shown in the bright field/immunofluorescence photographs of lung sections from a fatal asthma patient (described as patient 2 in a study by Fujisawa and colleagues, Ref. 75) . However, attempts to detect the release of ESGPs from eosinophils recruited to the lung in response to an OVA aerosol challenge have proven futile. The immunofluorescence photographs of lung sections from OVA-sensitized/challenged mice stained with either anti-mouse MBP-1 or a marker of EPO activity (i.e., anti-nitrotyrosine), demonstrate that both ESGPs remain associated only with intact eosinophils recruited to the lung. No evidence of extracellular matrix deposition of either ESGP is observed.
